Učitavanje...
A73 COST-EFFECTIVENESS OF INFLIXIMAB BIOSIMILAR COMPARED TO ORIGINATOR INFLIXIMAB FOR THE MANAGEMENT OF CROHN’S DISEASE
BACKGROUND: Originator infliximab (marketed as Remicade) was the first biological therapy approved in patients with Crohn’s Disease (CD), and has been proven to be effective for the induction and maintenance of remission in patients with moderate-to-severe disease. Due to its recent patent expiry, a...
Spremljeno u:
| Izdano u: | J Can Assoc Gastroenterol |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6508372/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.073 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|